Development and in vitro evaluation of a liposome based implant formulation for the decapeptide cetrorelix
- 1 April 2005
- journal article
- research article
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 59 (3) , 439-448
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Determination of the size distribution of liposomes by SEC fractionation, and PCS analysis and enzymatic assay of lipid contentAAPS PharmSciTech, 2002
- Peptide analogs in the therapy of prostate cancerThe Prostate, 2000
- Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis☆Peptides, 1999
- Erosion and controlled release properties of semisolid vesicular phospholipid dispersionsJournal of Controlled Release, 1998
- Three-dimensional liposome networks: freeze fracture electron microscopical evaluation of their structure and in vitro analysis of release of hydrophilic markersAdvanced Drug Delivery Reviews, 1997
- Seven-day administration of the gonadotropin-releasing hormone antagonist Cetrorelix in normal cycling womenEuropean Journal of Endocrinology, 1994
- Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulationHuman Reproduction, 1994
- Responses to the antagonistic analog of LH-RH (SB-75, cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancerThe Prostate, 1994
- Liposome Preparation by a New High Pressure Homogenizer Gaulin Micron Lab 40Drug Development and Industrial Pharmacy, 1990
- New antagonists of LHRH II. Inhibition and potentiation of LHRH by closely related analoguesInternational Journal of Peptide and Protein Research, 1988